What can the CEO of Redx Pharma tell us about attracting investment? [video]

During the recent HealthEx London forum at One George Street, Westminster, Biotech and Money had the opportunity to interview several CEOs from highly successful, leading biotech and investment firms.

In this video we talk to Neil Murray, CEO of Redx Pharma. With over twenty five years’ worth of experience in the pharmaceutical industry, Neil has worked for a number of leading companies, including Solutia, Vernalis, Sigma Aldrich and GlaxoWellcome.

Having assumed several important R&D, commercial and operational roles during his career, Neil’s experience in the industry ranges from drug discovery and development through to commercialisation, marketing and sales directing.

Having recently listing on AIM, Redx have gone from strength to strength under Neil’s leadership, and he has recently raised in excess of £20 million in investment through both high net-worth investors and regional growth fund capital.

For this interview, we ask what makes Redx such an attractive target for these investors; we ask Neil for his views on the current climate surrounding the UK life sciences sector, how it can best attract investment and what challenges it will face in the near future; we also ask what the biggest challenges are for biotech company CEOs in the current environment. As CEO of a global pharmaceutical company that deals in anti-infectives, immunology and oncology, Neil’s insight into the UK market proves to be invaluable.

Click the image to view the short video.

Other videos in this series includes short interviews with Jim Phillips, CEO, Midatech Pharma, Justin Gover, CEO, GW Pharmaceuticals, Gil Bar-Nahum, Managing Director, Global Healthcare Investment Banking, Jefferies & Co. and Wolfgang Rencken, CEO, Sphere Medical.

To enquire about involvement in our 2016 HealthEx London forum, taking place during Biotech and Money London 2016 on 2-3 February as a Partner click here. If you are interested in being selected as a delegate click here.

Tags :

Leave a comment